Primary Site >> Pancreatic Cancer
Gene >> RRM1
| 1. | |||||||||||
| Journal: | Cancer Res. 2006 Apr 1;66(7):3928-35. | ||||||||||
| Title: | Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. | ||||||||||
| Author: | Giovannetti, Elisa|Del Tacca, Mario|Mey, Valentina|Funel, Niccola|Nannizzi, Sara|Ricci, Sergio|Orlandini, Cinzia|Boggi, Ugo|Campani, Daniela|Del Chiaro, Marco|Iannopollo, Mauro|Bevilacqua, Generoso|Mosca, Franco|Danesi, Romano | ||||||||||
| PMID: | 16585222 | ||||||||||
| 2. | |||||||||||
| Journal: | Int J Cancer. 2007 Mar 15;120(6):1355-63. | ||||||||||
| Title: | Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. | ||||||||||
| Author: | Nakahira, Shin|Nakamori, Shoji|Tsujie, Masanori|Takahashi, Yuji|Okami, Jiro|Yoshioka, Shinichi|Yamasaki, Makoto|Marubashi, Shigeru|Takemasa, Ichiro|Miyamoto, Atsushi|Takeda, Yutaka|Nagano, Hiroaki|Dono, Keizo|Umeshita, Koji|Sakon, Masato|Monden, Morito | ||||||||||
| PMID: | 17131328 | ||||||||||
| 3. | |||||||||||
| Journal: | Br J Cancer. 2007 Feb 12;96(3):457-63. | ||||||||||
| Title: | Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. | ||||||||||
| Author: | Nakano, Y|Tanno, S|Koizumi, K|Nishikawa, T|Nakamura, K|Minoguchi, M|Izawa, T|Mizukami, Y|Okumura, T|Kohgo, Y | ||||||||||
| PMID: | 17224927 | ||||||||||
| 4. | |||||||||||
| Journal: | Anticancer Res. 2008 Jul-Aug;28(4B):2205-12. | ||||||||||
| Title: | Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. | ||||||||||
| Author: | Ohhashi, Seiji|Ohuchida, Kenoki|Mizumoto, Kazuhiro|Fujita, Hayato|Egami, Takuya|Yu, Jun|Toma, Hiroki|Sadatomi, Shoko|Nagai, Eishi|Tanaka, Masao | ||||||||||
| PMID: | 18751396 | ||||||||||
| 5. | |||||||||||
| Journal: | Oncogene. 2009 Aug 13;28(32):2903-9. | ||||||||||
| Title: | Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. | ||||||||||
| Author: | Akita, H|Zheng, Z|Takeda, Y|Kim, C|Kittaka, N|Kobayashi, S|Marubashi, S|Takemasa, I|Nagano, H|Dono, K|Nakamori, S|Monden, M|Mori, M|Doki, Y|Bepler, G | ||||||||||
| PMID: | 19543324 | ||||||||||
| 6. | |||||||||||
| Journal: | Cancer Invest. 2010 Feb;28(2):172-80. | ||||||||||
| Title: | In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. | ||||||||||
| Author: | Metro, G|Zheng, Z|Fabi, A|Schell, M|Antoniani, B|Mottolese, M|Monteiro, A N|Vici, P|Lara Rivera, S|Boulware, D|Cognetti, F|Bepler, G | ||||||||||
| PMID: | 19968494 | ||||||||||
| 7. | |||||||||||
| Journal: | Clin Cancer Res. 2010 Jan 1;16(1):320-9. | ||||||||||
| Title: | Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. | ||||||||||
| Author: | Okazaki, Taro|Javle, Milind|Tanaka, Motofumi|Abbruzzese, James L|Li, Donghui | ||||||||||
| PMID: | 20028759 | ||||||||||
| 8. | |||||||||||
| Journal: | Int J Oncol. 2010 Feb;36(2):341-9. | ||||||||||
| Title: | Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. | ||||||||||
| Author: | Mitsuno, Mayumi|Kitajima, Yoshihiko|Ohtaka, Kazuma|Kai, Keita|Hashiguchi, Kazuyoshi|Nakamura, Jun|Hiraki, Masatsugu|Noshiro, Hirokazu|Miyazaki, Kohji | ||||||||||
| PMID: | 20043067 | ||||||||||
| 9. | |||||||||||
| Journal: | Cancer. 2010 Nov 15;116(22):5325-35. | ||||||||||
| Title: | Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. | ||||||||||
| Author: | Tanaka, Motofumi|Javle, Milind|Dong, Xiaoqun|Eng, Cathy|Abbruzzese, James L|Li, Donghui | ||||||||||
| PMID: | 20665488 | ||||||||||
| 10. | |||||||||||
| Journal: | Cancer. 2011 Jul 15;117(14):3126-34. | ||||||||||
| Title: | Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. | ||||||||||
| Author: | Kim, Richard|Tan, Ann|Lai, Kevin K|Jiang, John|Wang, Yixen|Rybicki, Lisa A|Liu, Xiulu | ||||||||||
| PMID: | 21264835 | ||||||||||
| 11. | |||||||||||
| Journal: | Int J Oncol. 2011 Aug;39(2):473-82. | ||||||||||
| Title: | Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. | ||||||||||
| Author: | Kurata, Nobuaki|Fujita, Hayato|Ohuchida, Kenoki|Mizumoto, Kazuhiro|Mahawithitwong, Prawej|Sakai, Hiroshi|Onimaru, Manabu|Manabe, Tatsuya|Ohtsuka, Takao|Tanaka, Masao | ||||||||||
| PMID: | 21617862 | ||||||||||
| 12. | |||||||||||
| Journal: | Pancreas. 2011 Jul;40(5):657-63. | ||||||||||
| Title: | Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. | ||||||||||
| Author: | Zeng, Hongmei|Yu, Herbert|Lu, Lingeng|Jain, Dhanpat|Kidd, Mark S|Saif, M Wasif|Chanock, Stephen J|Hartge, Patricia|Risch, Harvey A | ||||||||||
| PMID: | 21487324 | ||||||||||
| 13. | |||||||||||
| Journal: | Cancer Sci. 2011 Mar;102(3):622-9. | ||||||||||
| Title: | Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd). | ||||||||||
| Author: | Nishio, Ren|Tsuchiya, Hiroyuki|Yasui, Toshihiro|Matsuura, Shizuka|Kanki, Keita|Kurimasa, Akihiro|Hisatome, Ichiro|Shiota, Goshi | ||||||||||
| PMID: | 21205085 | ||||||||||
| 14. | |||||||||||
| Journal: | Lancet Oncol. 2011 Jul;12(7):693-702. | ||||||||||
| Title: | The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. | ||||||||||
| Author: | Jordheim, Lars Petter|Seve, Pascal|Tredan, Olivier|Dumontet, Charles | ||||||||||
| PMID: | 21163702 | ||||||||||
| 15. | |||||||||||
| Journal: | Invest New Drugs. 2012 Jun;30(3):1164-74. | ||||||||||
| Title: | A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. | ||||||||||
| Author: | Oh, Do-Youn|Lee, Keun Wook|Lee, Kyung-Hee|Sohn, Chang-Hak|Park, Young Suk|Zang, Dae Young|Ryoo, Hun-Mo|Song, Hong-Suk|Kim, Jin-Soo|Kang, Hye-Jin|Kim, Bong-Seog|Bang, Yung-Jue | ||||||||||
| PMID: | 21404106 | ||||||||||
| 16. | |||||||||||
| Journal: | Hepatogastroenterology. 2012 Jul-Aug;59(117):1609-13. | ||||||||||
| Title: | Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. | ||||||||||
| Author: | Kasuya, Kazuhiko|Tsuchida, Akihiko|Nagakawa, Yuichi|Suzuki, Yoshiaki|Suzuki, Minako|Aoki, Tatsuya|Abe, Yuta|Shimazu, Motohide|Itoi, Takao|Sofuni, Atsushi | ||||||||||
| PMID: | 22155850 | ||||||||||
| 17. | |||||||||||
| Journal: | BMC Cancer. 2012 Mar 22;12:104. | ||||||||||
| Title: | Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? | ||||||||||
| Author: | Valsecchi, Matias E|Holdbrook, Thomas|Leiby, Benjamin E|Pequignot, Edward|Littman, Susan J|Yeo, Charles J|Brody, Jonathan R|Witkiewicz, Agnieszka K | ||||||||||
| PMID: | 22436573 | ||||||||||
| 18. | |||||||||||
| Journal: | Chin J Cancer. 2012 Oct;31(10):476-83. | ||||||||||
| Title: | Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma. | ||||||||||
| Author: | Zhao, Li-Ping|Xue, Cong|Zhang, Jian-Wei|Hu, Zhi-Huang|Zhao, Yuan-Yuan|Zhang, Jing|Huang, Yan|Zhao, Hong-Yun|Zhang, Li | ||||||||||
| PMID: | 22692073 | ||||||||||
| 19. | |||||||||||
| Journal: | Asian Pac J Cancer Prev. 2013;14(7):4261-5. | ||||||||||
| Title: | Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. | ||||||||||
| Author: | Zhang, Xiong|Jin, Fen-Shu|Zhang, Li-Guo|Chen, Rui-Xue|Zhao, Jin-Hui|Wang, Yan-Nan|Wang, En-Fu|Jiang, Zhen-Dong | ||||||||||
| PMID: | 23991987 | ||||||||||
| 20. | |||||||||||
| Journal: | Hepatogastroenterology. 2013 Sep;60(126):1484-7. | ||||||||||
| Title: | In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells. | ||||||||||
| Author: | Murata, Akihiro|Nakata, Bunzo|Komoto, Masahiro|Hirata, Keiichiro|Kimura, Kenjiro|Amano, Ryosuke|Hirakawa, Kosei | ||||||||||
| PMID: | 23933942 | ||||||||||
| 21. | |||||||||||
| Journal: | Biomark Med. 2013 Aug;7(4):663-71. | ||||||||||
| Title: | Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer? | ||||||||||
| Author: | Jordheim, Lars Petter|Dumontet, Charles | ||||||||||
| PMID: | 23905902 | ||||||||||
| 22. | |||||||||||
| Journal: | Surgery. 2013 Apr;153(4):565-75. | ||||||||||
| Title: | Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gem | ||||||||||
| Author: | Nakagawa, Naoya|Murakami, Yoshiaki|Uemura, Kenichiro|Sudo, Takeshi|Hashimoto, Yasushi|Kondo, Naru|Sueda, Taijiro | ||||||||||
| PMID: | 23253379 | ||||||||||
| 23. | |||||||||||
| Journal: | Oncogene. 2013 Mar 28;32(13):1714-23. | ||||||||||
| Title: | The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. | ||||||||||
| Author: | Skrypek, N|Duchene, B|Hebbar, M|Leteurtre, E|van Seuningen, I|Jonckheere, N | ||||||||||
| PMID: | 22580602 | ||||||||||
| 24. | |||||||||||
| Journal: | Cancer. 2013 Jan 15;119(2):445-53. | ||||||||||
| Title: | An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implication | ||||||||||
| Author: | Fisher, Sarah B|Patel, Sameer H|Bagci, Pelin|Kooby, David A|El-Rayes, Bassel F|Staley, Charles A 3rd|Adsay, N Volkan|Maithel, Shishir K | ||||||||||
| PMID: | 22569992 | ||||||||||
| 25. | |||||||||||
| Journal: | World J Surg Oncol. 2013 May 27;11:117. | ||||||||||
| Title: | Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone. | ||||||||||
| Author: | Murata, Akihiro|Amano, Ryosuke|Yamada, Nobuya|Kimura, Kenjiro|Yashiro, Masakazu|Nakata, Bunzo|Hirakawa, Kosei | ||||||||||
| PMID: | 23710668 | ||||||||||
| 26. | |||||||||||
| Journal: | JOP. 2014 Jul 28;15(4):299-302. | ||||||||||
| Title: | Pharmacogenetics in neuroendocrine tumors of the pancreas. | ||||||||||
| Author: | Rizvi, Syed Mujtaba|Wong, Joyce|Saif, Muhammad Wasif|Jia, Yuxia | ||||||||||
| PMID: | 25076325 | ||||||||||
| 27. | |||||||||||
| Journal: | Anticancer Drugs. 2015 Jan;26(1):90-100. | ||||||||||
| Title: | Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones. | ||||||||||
| Author: | Yoneyama, Hiroshi|Takizawa-Hashimoto, Asako|Takeuchi, Osamu|Watanabe, Yukiko|Atsuda, Koichiro|Asanuma, Fumiki|Yamada, Yoshinori|Suzuki, Yukio | ||||||||||
| PMID: | 25187316 | ||||||||||
| 28. | |||||||||||
| Journal: | Oncol Rep. 2015 Jan;33(1):383-90. | ||||||||||
| Title: | Establishment of human pancreatic cancer gemcitabineresistant cell line with ribonucleotide reductase overexpression. | ||||||||||
| Author: | Wang, Congfei|Zhang, Weiwei|Fu, Mingjuan|Yang, Aiqin|Huang, Heguang|Xie, Jieming | ||||||||||
| PMID: | 25394408 | ||||||||||
| 29. | |||||||||||
| Journal: | J Pharmacol Sci. 2015 Mar;127(3):319-25. | ||||||||||
| Title: | Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. | ||||||||||
| Author: | Minami, Kentaro|Shinsato, Yoshinari|Yamamoto, Masatatsu|Takahashi, Homare|Zhang, Shaoxuan|Nishizawa, Yukihiko|Tabata, Sho|Ikeda, Ryuji|Kawahara, Kohich|Tsujikawa, Kazutake|Chijiiwa, Kazuo|Yamada, Katsushi|Akiyama, Shin-ichi|Perez-Torras, Sandra|Pastor-Ang | ||||||||||
| PMID: | 25837929 | ||||||||||
| 30. | |||||||||||
| Journal: | Clin Cancer Res. 2015 Dec 15;21(24):5563-77. | ||||||||||
| Title: | The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1). | ||||||||||
| Author: | Vena, Francesca|Li Causi, Eleonora|Rodriguez-Justo, Manuel|Goodstal, Samantha|Hagemann, Thorsten|Hartley, John A|Hochhauser, Daniel | ||||||||||
| PMID: | 26228206 | ||||||||||
| 31. | |||||||||||
| Journal: | World J Gastrointest Oncol. 2015 Sep 15;7(9):132-40. | ||||||||||
| Title: | Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review. | ||||||||||
| Author: | Borazanci, Erkut|Millis, Sherri Z|Korn, Ron|Han, Haiyong|Whatcott, Clifford J|Gatalica, Zoran|Barrett, Michael T|Cridebring, Derek|Von Hoff, Daniel D | ||||||||||
| PMID: | 26380056 | ||||||||||
| 32. | |||||||||||
| Journal: | Contemp Oncol (Pozn). 2015;19(3):207-13. | ||||||||||
| Title: | ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. | ||||||||||
| Author: | Ulker, Mehmet|Duman, Berna Bozkurt|Sahin, Berksoy|Gumurdulu, Derya | ||||||||||
| PMID: | 26557761 | ||||||||||
| 33. | |||||||||||
| Journal: | Pancreas. 2016 Nov;45(10):1485-1493. | ||||||||||
| Title: | Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. | ||||||||||
| Author: | Farrell, James J|Moughan, Jennifer|Wong, Jonathan L|Regine, William F|Schaefer, Paul|Benson, Al B 3rd|Macdonald, John S|Liu, Xiyong|Yen, Yun|Lai, Raymond|Zheng, Zhong|Bepler, Gerold|Guha, Chandan|Elsaleh, Hany | ||||||||||
| PMID: | 27748721 | ||||||||||
| 34. | |||||||||||
| Journal: | Cancer Lett. 2016 Apr 1;373(1):130-137. | ||||||||||
| Title: | MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. | ||||||||||
| Author: | Fan, Pei|Liu, Li|Yin, Yefeng|Zhao, Zhefu|Zhang, Yiyao|Amponsah, Prince S|Xiao, Xi|Bauer, Nathalie|Abukiwan, Alia|Nwaeburu, Clifford C|Gladkich, Jury|Gao, Chao|Schemmer, Peter|Gross, Wolfgang|Herr, Ingrid | ||||||||||
| PMID: | 26828016 | ||||||||||
| 35. | |||||||||||
| Journal: | Mol Med Rep. 2017 Apr;15(4):1461-1470. | ||||||||||
| Title: | Sclareolide enhances gemcitabineinduced cell death through mediating the NICD and Gli1 pathways in gemcitabineresistant human pancreatic cancer. | ||||||||||
| Author: | Chen, Sheng|Wang, Ye|Zhang, Wen-Long|Dong, Mao-Sheng|Zhang, Jian-Hua | ||||||||||
| PMID: | 28259943 | ||||||||||
| 36. | |||||||||||
| Journal: | J Gastrointest Oncol. 2017 Feb;8(1):164-172. | ||||||||||
| Title: | Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. | ||||||||||
| Author: | Borazanci, Erkut|Millis, Sherri Z|Kimbrough, Jeffery|Doll, Nancy|Von Hoff, Daniel|Ramanathan, Ramesh K | ||||||||||
| PMID: | 28280620 | ||||||||||
| 37. | |||||||||||
| Journal: | Front Pharmacol. 2017 Mar 27;8:155. | ||||||||||
| Title: | Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine. | ||||||||||
| Author: | Grixti, Justine M|O'Hagan, Steve|Day, Philip J|Kell, Douglas B | ||||||||||
| PMID: | 28396636 | ||||||||||
| 38. | |||||||||||
| Journal: | Oncol Lett. 2017 May;13(5):3423-3430. | ||||||||||
| Title: | Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine. | ||||||||||
| Author: | Aoyama, Toru|Miyagi, Yohei|Murakawa, Masaaki|Yamaoku, Koichiro|Atsumi, Yosuke|Shiozawa, Manabu|Ueno, Makoto|Morimoto, Manabu|Oshima, Takashi|Yukawa, Norio|Yoshikawa, Takaki|Rino, Yasushi|Masuda, Munetaka|Morinaga, Soichiro | ||||||||||
| PMID: | 28521448 | ||||||||||
| 39. | |||||||||||
| Journal: | Cancer Chemother Pharmacol. 2017 Oct;80(4):765-775. | ||||||||||
| Title: | MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. | ||||||||||
| Author: | Rajabpour, Azam|Afgar, Ali|Mahmoodzadeh, Habibollah|Radfar, Jalal-E-Din|Rajaei, Farzad|Teimoori-Toolabi, Ladan | ||||||||||
| PMID: | 28887583 | ||||||||||
| 40. | |||||||||||
| Journal: | Oncol Lett. 2017 Nov;14(5):5400-5408. | ||||||||||
| Title: | Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization. | ||||||||||
| Author: | Yan, Tao|Li, Hai-Ying|Wu, Jian-Song|Niu, Qiang|Duan, Wei-Hong|Han, Qing-Zeng|Ji, Wang-Ming|Zhang, Tao|Lv, Wei | ||||||||||
| PMID: | 29098031 | ||||||||||
| 41. | |||||||||||
| Journal: | J Clin Pharm Ther. 2018 Apr;43(2):163-169. | ||||||||||
| Title: | Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis. | ||||||||||
| Author: | Han, Q L|Zhou, Y H|Lyu, Y|Yan, H|Dai, G H | ||||||||||
| PMID: | 29214667 | ||||||||||
| 42. | |||||||||||
| Journal: | Oncol Rep. 2018 Mar;39(3):1322-1330. | ||||||||||
| Title: | CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. | ||||||||||
| Author: | Liang, Min|Zhao, Tiangang|Ma, Linfeng|Guo, Yingjie | ||||||||||
| PMID: | 29286153 | ||||||||||
| 43. | |||||||||||
| Journal: | Br J Cancer. 2018 Apr;118(8):1084-1088. | ||||||||||
| Title: | Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. | ||||||||||
| Author: | Elander, N O|Aughton, K|Ghaneh, P|Neoptolemos, J P|Palmer, D H|Cox, T F|Campbell, F|Costello, E|Halloran, C M|Mackey, J R|Scarfe, A G|Valle, J W|McDonald, A C|Carter, R|Tebbutt, N C|Goldstein, D|Shannon, J|Dervenis, C|Glimelius, B|Deakin, M|Charnley, R M| | ||||||||||
| PMID: | 29523831 | ||||||||||
| 44. | |||||||||||
| Journal: | Oncotarget. 2018 Jun 19;9(47):28434-28444. | ||||||||||
| Title: | Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. | ||||||||||
| Author: | Shinoda, Shuhei|Kaino, Seiji|Amano, Shogo|Harima, Hirofumi|Matsumoto, Toshihiko|Fujisawa, Koichi|Takami, Taro|Yamamoto, Naoki|Yamasaki, Takahiro|Sakaida, Isao | ||||||||||
| PMID: | 29983871 | ||||||||||
| 45. | |||||||||||
| Journal: | Pancreatology. 2018 Aug 22. pii: S1424-3903(18)30658-6. | ||||||||||
| Title: | Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer. | ||||||||||
| Author: | Liu, JieFeng|Hu, GuoHuang|Gong, YuJing|Yu, QianLe|He, Bin|Li, WangHao|He, ZhiGuo|Hao, WenJie|He, ZiChao|Liu, YiPing | ||||||||||
| PMID: | 30316690 | ||||||||||